Skip to main content
APGE
NASDAQ Life Sciences

Apogee Therapeutics 以每股 70 美元的价格定价 3.5 亿美元的发行，随着积极的试验数据而来

feedReported by Reuters
Sentiment info
Neutral
Importance info
8
Price
$73.8
Mkt Cap
$5.072B
52W Low
$26.2
52W High
$84.56
Market data snapshot near publication time

summarizeSummary

Apogee Therapeutics 已将其承销的公开发行定价为 3.5 亿美元，以每股 70.00 美元的价格出售 500 万股。这代表了与之前宣布的 3 亿美元发行相比的增加。这次资金募集是在 3 月 23 日报告了其领先候选药物 zumilokibart 的极为积极的 52 周第 2 期临床试验数据之后进行的。大量的资本注入将显著增加公司的财务跑道，以用于持续的临床开发。虽然发行价格低于当前的市场价格，意味着现有股东存在一些稀释，但这是为了利用最近的积极数据并资助未来增长而采取的战略举动。交易者将会关注市场对稀释和公司部署新筹集的资本计划的反应。

在该公告发布时，APGE的交易价格为$73.80，交易所为NASDAQ，所属行业为Life Sciences，市值约为$50.7亿。 52周交易区间为$26.20至$84.56。 这则新闻被评估为中性市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed APGE - Latest Insights

APGE
Mar 25, 2026, 4:53 PM EDT
Source: Wiseek News
Importance Score:
9
$377.4M Equity Offering Finalized by Apogee Therapeutics, Underwriters Exercise Full Option
Sentiment: Neutral
View Wiseek Article
APGE
Mar 25, 2026, 4:44 PM EDT
Filing Type: 8-K
Importance Score:
8
Apogee Therapeutics Finalizes $402.5M Public Offering at $70.00/Share
Sentiment: Negative
View Wiseek Article
APGE
Mar 25, 2026, 4:40 PM EDT
Filing Type: 424B5
Importance Score:
8
Apogee Therapeutics Prices $350M Public Offering at $70.00/Share Following Positive Clinical Data
Sentiment: Neutral
View Wiseek Article
APGE
Mar 24, 2026, 9:54 PM EDT
Source: Reuters
Importance Score:
8
Apogee Therapeutics Prices $350M Offering at $70/Share Following Positive Trial Data
Sentiment: Neutral
View Wiseek Article
APGE
Mar 23, 2026, 4:28 PM EDT
Filing Type: 424B5
Importance Score:
8
Apogee Therapeutics Launches $300M Public Offering Following Positive Phase 2 Data
Sentiment: Neutral
View Wiseek Article
APGE
Mar 23, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Apogee Therapeutics Proposes $300M Public Offering Following Positive Clinical Data
Sentiment: Neutral
View Wiseek Article
APGE
Mar 23, 2026, 6:36 AM EDT
Filing Type: 8-K
Importance Score:
9
Apogee Therapeutics Reports Strong 52-Week Phase 2 Data for Zumilokibart in Atopic Dermatitis
Sentiment: Positive
View Wiseek Article
APGE
Mar 23, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Apogee's Zumilokibart Delivers Strong 52-Week Phase 2 Data in Atopic Dermatitis, Showing Durable Efficacy with Quarterly/Biannual Dosing
Sentiment: Positive
View Wiseek Article
APGE
Mar 02, 2026, 7:25 AM EST
Source: Unknown
Importance Score:
7
Apogee Therapeutics Reports $0 Revenue, $(4.22) EPS in 2025 10-K Amid Heavy R&D Investment
Sentiment: Negative
View Wiseek Article
APGE
Mar 02, 2026, 7:20 AM EST
Filing Type: 10-K
Importance Score:
9
Apogee Therapeutics Reports Strong Clinical Progress for Lead Candidate, Secures Long Runway into 2028
Sentiment: Positive
View Wiseek Article